Phase II Study of a Quadruple-modality Therapy for Resectable Stage Discrete N2 III A-B Non-small Cell Lung Cancer (WJOG12119L: SQUAT trial)
Phase 2
Completed
- Conditions
- non-small-cell lung cancer
- Registration Number
- JPRN-jRCT2080224981
- Lead Sponsor
- Tetsuya Mitsudomi (Coordinating Investigator)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 31
Inclusion Criteria
1.Patients with a histologically confirmed diagnosis of NSCLC
2.Clinical Stage T1-3N2 III A-B or T4N2 IIIB (solid diameter > 7cm)
3.Patients who were not previously treated for NSCLC
4. Patients who is possible to undergo complete resection
5. Patients to start radiation therapy based on the protocol in this study.
Exclusion Criteria
1.Patients with active multiple primary cancer
2.Patients with autoimmune disorder including the history of treatment by immunosuppressive agent
3.Patients with interstitial lung disease on CT scan,
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method